You are now leaving Lundbeck UK's website (www.lundbeck.com/uk) for an external website. External links are provided as a resource to the viewer. Lundbeck UK are not responsible for the external website and its content.
UK-NOTPR-1010 | April 2022
Lundbeck became a signatory to the UN Global Compact in 2009. We continue to promote initiatives that demonstrate our commitment to the 10 principles on human and labour rights, environmental protection and anti-corruption.
Executive Management assesses Lundbeck’s business risks and opportunities and establishes our sustainability targets as communicated in our annual report.
We release an annual sustainability report with our Communication on Progress report to the UN Global Compact, describing in detail our sustainability performance and targets. For over a decade, we have reported on our sustainability efforts, challenges and contributions to our business, stakeholders and the societies we operate within.
In 2020, we based the key aspects of our sustainability strategy on the UN Sustainable Development Goals (SDGs). We found we have a significant impact on seven of the 17 Goals:
Key examples are Goal 3 that is closely linked to our corporate purpose and dedication to restore brain health and Goal 13 that drives our efforts to prepare for a zero emissions future. We will use our influence and act to promote Goals 5, 8, 12 and 16. Across our sustainability actions we are seeking partnerships with others to enable change and maximise impact (Goal 17).
We are dedicated to improving access to brain health in accordance with WHO.
Saving energy and reducing CO2 emissions are strategic priorities for Lundbeck.
We may provide donations and grants to eligible and appropriate purposes.
We offer our employees a sound physical and mental work environment.
With our own manufacturing processes, we obtain several sustainable opportunities.
We pursue our business purpose guided by several pillars and our Code of Conduct.
How we engage with third parties and suppliers to deliver treatments for patients.
How we commit to transparency in the transfer and interactions of value.
UK-NOTPR-0527 | April 2022